Quest Diagnostics Incorporated
Leadership History
4 leaders · 1996 to present
James Davis is the CEO of Quest Diagnostics, in the role since 2022. The first chief executive was Kenneth W. Freeman, from 1996.
| Name | Role | From | To | Years in role |
|---|---|---|---|---|
| Jim Davis | Chairman, CEO, and President | 2022 | Present | 4 |
| Steve Rusckowski | Chairman, President, and CEO | 2012 | 2022 | 10 |
| Surya Mohapatra | Chairman, President, and CEO | 2004 | 2012 | 8 |
| Kenneth W. Freeman | Chairman and CEO | 1996 | 2004 | 8 |
Quest Diagnostics is a Secaucus, New Jersey-based provider of diagnostic information services. It does not make drugs or run hospitals. It runs the labs that process blood, urine and tissue samples ordered by doctors, hospitals, employers and consumers, then sends results back through EHRs and the MyQuest app. Quest says it serves about one in three adult Americans and half the physicians and hospitals in the U.S. each year. Since 2024 it has also run LifeLabs in Canada. Quest Diagnostics was founded in 1967 in New York City by Dr. Paul A. Brown as Metropolitan Pathology Laboratory before spinning off from Corning in 1996 to become America’s largest commercial clinical diagnostic testing provider.
Quest Diagnostics earns fee-for-service revenue for lab tests ordered by physicians, hospitals, health plans, employers and consumers. Diagnostic Information Services (DIS) produced $2.978B of the company's $3.043B Q2 2026 revenue. Payment comes from commercial insurers, Medicare and Medicaid, hospitals that send it outreach or reference work, employers, and patients paying directly through questhealth.com. Volume drives the economics. Specimens collected at about 2,200 patient service centers and physician offices are moved by courier, and on some routes by air, to regional labs. High-throughput automated testing there keeps the cost per test low. Routine tests such as metabolic panels, lipid panels and blood counts make up most of the volume. Advanced diagnostics like AD-Detect Alzheimer's blood tests, Haystack MRD, genetics and cardiometabolic panels carry higher prices. Hospital outreach acquisitions and Co-Lab lab-management deals add volume.
Chairman, CEO, and President
2022 – Present
4 years (current)
Davis became CEO in November 2022 and Chairman in April 2023. He has led the LifeLabs acquisition, the Fresenius Spectra asset deal, the Corewell Health joint venture and further hospital outreach deals. He has also expanded AD-Detect, Haystack MRD and consumer testing. Under him, Quest raised FY2026 guidance twice and increased the dividend 7.5% to $0.86 per quarter.
Chairman, President, and CEO
2012 – 2022
10 years
Rusckowski transformed Quest into a leader in diagnostic information services with strong financial performance. He focused on health system partnerships, operational excellence, advanced diagnostics, and consumer testing. He launched Quest for Health Equity ($100 million commitment) and led the COVID-19 pandemic response. He expanded the board to 40% women and increased diversity.
Chairman, President, and CEO
2004 – 2012
8 years
Mohapatra expanded Quest's international presence and technology capabilities. He led the company through the AmeriPath acquisition and the 2008-2009 financial crisis, though growth slowed during his tenure.
Chairman and CEO
1996 – 2004
8 years
Freeman led Quest through the 1996 spin-off from Corning and the transformative 1999 SmithKline Beecham Clinical Laboratories acquisition. He established the acquisition-driven growth strategy and public company infrastructure.
Quest Diagnostics faces reimbursement pressure, PAMA-related Medicare risk, labor and logistics costs, acquisition integration, health-system competition, billing complexity, cybersecurity risk, regulation, and the need to maintain fast, accurate test processing at national scale.
Prominent CEOs in Quest's history include Kenneth W. Freeman (1995 to 2004), Surya N. Mohapatra (2004 to 2012), Steve Rusckowski (2012 to 2022), and current Chairman, President, and CEO James E. Davis (2022, present).
Kenneth Freeman led the transformation of Corning Clinical Laboratories into an independent, publicly traded corporation in 1996, renaming it Quest Diagnostics and executing the landmark $1.3 billion acquisition of SmithKline Beecham Clinical Laboratories in 1999.
Over a decade of leadership, Steve Rusckowski transformed Quest through his 'two-point strategy' (accelerating growth and driving operational excellence), executing dozens of hospital lab acquisitions, constructing the Clifton mega-lab, partnering with Walmart, and leading America's large diagnostic testing response during the COVID-19 pandemic.
Jim Davis became CEO in November 2022 and Chairman in 2023. A seasoned healthcare executive with degrees from MIT and an MBA from Harvard, Davis previously led General Diagnostics at Quest and held senior executive roles at GE Healthcare, bringing deep operational and diagnostic technology expertise.
Under Steve Rusckowski and Jim Davis, Quest scaled commercial COVID-19 molecular PCR testing from zero to hundreds of thousands of tests daily, investing in high-throughput robotics and delivering over 100 million COVID tests to protect American public health.
Jim Davis has established three core priorities: accelerating organic growth in advanced esoteric oncology and genomic testing, expanding health system outreach lab M&A, and driving continuous productivity savings through artificial intelligence and laboratory automation.
Quest's leadership culture is centered on its five Core Values: Quality, Integrity, Innovation, Accountability, Collaboration, and Leadership, driven by its unifying purpose: 'Working together to create a healthier world, one life at a time'.
Quest has been continuously recognized as one of Fortune's 'World's Most Admired Companies', named on the Dow Jones Sustainability Index, and celebrated for outstanding corporate diversity, disability inclusion, and clinical quality standards.
James E. (Jim) Davis is the Chairman, President, and Chief Executive Officer of Quest Diagnostics, having assumed the CEO role in November 2022 and the Chairman role in May 2023.
Jim Davis joined Quest in 2013, serving as Senior Vice President of Diagnostic Solutions and later Executive Vice President of General Diagnostics, leading the commercial laboratory business, hospital partnerships, and digital platforms.
Davis focuses on accelerating hospital outreach laboratory acquisitions, expanding consumer-initiated testing through Quest Health, growing advanced oncology and autoimmune testing, and driving operational automation.
Steve Rusckowski served as CEO from 2012 to 2022, transforming Quest into a healthcare services powerhouse, divesting non-core clinical trial operations, establishing hospital lab outreach partnerships, and leading the national COVID-19 testing response.
Dr. Surya N. Mohapatra served as CEO from 2004 to 2012, driving significant esoteric testing expansion, international ventures in India and the UK, and pioneering molecular oncology diagnostics.
Ken Freeman was CEO from 1995 to 2004, orchestrating the 1996 spin-off from Corning, leading the corporate rebranding to Quest Diagnostics, and executing the transformational $1.3B SmithKline Beecham clinical lab acquisition in 1999.
Dr. Paul A. Brown founded Metropolitan Pathology Laboratory in 1967, pioneering commercial outpatient medical testing and establishing 24-hour automated lab testing models that revolutionized American medical diagnostics.
Quest’s leadership culture is centered on clinical quality, patient safety, medical ethics, continuous operational improvement (Six Sigma and Quest Management System), and community health stewardship.
Compare executive leadership tenures and strategic transitions
Explore Quest Diagnostics
Core profile pages, founders and related research hubs for this company.